{
  "doc_id": "22",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "《基于肠促胰素的药物治疗临床应用的快速建议指南》",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "《基于肠促胰素的药物治疗临床应用的快速建议指南》",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [],
          "relations": [],
          "sentence_en": "Rapid advice guideline for the clinical use of incretin-based drug therapy"
        }
      ],
      "paragraph_en": "Rapid advice guideline for the clinical use of incretin-based drug therapy"
    },
    {
      "paragraph_id": "1",
      "paragraph": "肠促胰素(incretin)是一种经食物刺激后由肠细胞分泌入血、能够刺激胰岛素分泌的激素。基于肠促胰素的治疗药物(incretin-based therapies，IBTs)通过与器官上的特异性受体结合，发挥类肠促胰素作用，从而达到降糖疗效。由于这类药物具有低血糖风险小和改善细胞功能等多方面的优势，逐渐在临床广泛使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "肠促胰素(incretin)是一种经食物刺激后由肠细胞分泌入血、能够刺激胰岛素分泌的激素。",
          "start_idx": 0,
          "end_idx": 45,
          "entities": [],
          "relations": [],
          "sentence_en": "Incretin is a hormone that is secreted into the blood by intestinal cells after food stimulation and can stimulate insulin secretion."
        },
        {
          "sentence_id": "1",
          "sentence": "基于肠促胰素的治疗药物(incretin-based therapies，IBTs)通过与器官上的特异性受体结合，发挥类肠促胰素作用，从而达到降糖疗效。",
          "start_idx": 45,
          "end_idx": 121,
          "entities": [],
          "relations": [],
          "sentence_en": "Incretin-based therapies (IBTs) bind to specific receptors on organs to exert incretin-like effects, thereby achieving the effect of lowering blood sugar."
        },
        {
          "sentence_id": "2",
          "sentence": "由于这类药物具有低血糖风险小和改善细胞功能等多方面的优势，逐渐在临床广泛使用。",
          "start_idx": 121,
          "end_idx": 160,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [],
          "sentence_en": "Because this type of drug has many advantages such as low risk of hypoglycemia and improved cell function, it has gradually been widely used in clinical practice."
        }
      ],
      "paragraph_en": "Incretin is a hormone that is secreted into the blood by intestinal cells after being stimulated by food and can stimulate insulin secretion. Incretin-based therapies (IBTs) bind to specific receptors on organs to exert incretin-like effects, thereby achieving a hypoglycemic effect. Due to the advantages of this type of drug, such as low risk of hypoglycemia and improved cell function, it has gradually been widely used in clinical practice."
    },
    {
      "paragraph_id": "2",
      "paragraph": "目前在国内已经上市了两种胰高血糖素样肽-1受体激动剂(Glucagon-likepeptide-1 receptoragonists，GLP-1RA)：包括艾塞那肽(Exenatide和利拉鲁肽(Liraglutide)，以及5种二肽基肽酶Ⅳ抑制剂(Dipeptidyl Peptidase- 4 inhibitor，DPP-4i)：包括西格列汀(Sitagliptin)、维格列汀(Vildagliptin)、沙格列汀(Saxagliptin)、利格列汀(Linagliptin)和阿格列汀(Alogliptin)(表1)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前在国内已经上市了两种胰高血糖素样肽-1受体激动剂(Glucagon-likepeptide-1 receptoragonists，GLP-1RA)：包括艾塞那肽(Exenatide和利拉鲁肽(Liraglutide)，以及5种二肽基肽酶Ⅳ抑制剂(Dipeptidyl Peptidase- 4 inhibitor，DPP-4i)：包括西格列汀(Sitagliptin)、维格列汀(Vildagliptin)、沙格列汀(Saxagliptin)、利格列汀(Linagliptin)和阿格列汀(Alogliptin)(表1)",
          "start_idx": 0,
          "end_idx": 262,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "胰高血糖素样肽-1受体激动剂(Glucagon-likepeptide-1 receptoragonists，GLP-1RA)",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 75,
              "entity_en": "Glucagon-like peptide-1 receptor agonists (GLP-1RA)"
            },
            {
              "entity_id": "T2",
              "entity": "艾塞那肽(Exenatide",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 92,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T3",
              "entity": "利拉鲁肽(Liraglutide)",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 110,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T4",
              "entity": "二肽基肽酶Ⅳ抑制剂(Dipeptidyl Peptidase- 4 inhibitor，DPP-4i)",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 166,
              "entity_en": "Dipeptidyl Peptidase- 4 inhibitor (DPP-4i)"
            },
            {
              "entity_id": "T5",
              "entity": "西格列汀(Sitagliptin)",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 186,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T6",
              "entity": "维格列汀(Vildagliptin)",
              "entity_type": "Drug",
              "start_idx": 187,
              "end_idx": 205,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T7",
              "entity": "沙格列汀(Saxagliptin)",
              "entity_type": "Drug",
              "start_idx": 206,
              "end_idx": 223,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T8",
              "entity": "利格列汀(Linagliptin)",
              "entity_type": "Drug",
              "start_idx": 224,
              "end_idx": 241,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T9",
              "entity": "阿格列汀(Alogliptin)",
              "entity_type": "Drug",
              "start_idx": 242,
              "end_idx": 258,
              "entity_en": "Alogliptin"
            }
          ],
          "relations": [],
          "sentence_en": "Currently, two glucagon-like peptide-1 receptor agonists (GLP-1RA) have been launched in China: Exenatide and Liraglutide, and five dipeptidyl peptidase-4 inhibitors (DPP-4i): Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin and Alogliptin (Table 1)."
        }
      ],
      "paragraph_en": "Currently, two glucagon-like peptide-1 receptor agonists (GLP-1RA) have been launched in China: Exenatide and Liraglutide, and five dipeptidyl peptidase-4 inhibitors (DPP-4i): Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin and Alogliptin (Table 1)."
    },
    {
      "paragraph_id": "3",
      "paragraph": "基于肠促胰素的治疗药物的出现为临床医生提供了更多选择，但它们的有效性、安全性和经济性究竟如何?基于肠促胰素的治疗药物在特殊人群(如老年患者)中使用有哪些注意事项?特别是这类药物在全球临床指南中地位变化迅速时，我们该如何评价、选择和应用?这些问题都有待于采用系统、科学的方法来回答。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "基于肠促胰素的治疗药物的出现为临床医生提供了更多选择，但它们的有效性、安全性和经济性究竟如何?基于肠促胰素的治疗药物在特殊人群(如老年患者)中使用有哪些注意事项?特别是这类药物在全球临床指南中地位变化迅速时，我们该如何评价、选择和应用?这些问题都有待于采用系统、科学的方法来回答。",
          "start_idx": 0,
          "end_idx": 140,
          "entities": [],
          "relations": [],
          "sentence_en": "The emergence of incretin-based therapeutic drugs has provided clinicians with more options, but what are their effectiveness, safety, and cost-effectiveness? What are the precautions for using incretin-based therapeutic drugs in special populations (such as elderly patients)? Especially when the status of this type of drug in global clinical guidelines is changing rapidly, how should we evaluate, select and apply it? These questions need to be answered using a systematic and scientific approach."
        }
      ],
      "paragraph_en": "The emergence of incretin-based therapeutic drugs has provided clinicians with more options, but what are their effectiveness, safety, and cost-effectiveness? What are the precautions for using incretin-based therapeutic drugs in special populations (such as elderly patients)? Especially when the status of this type of drug is changing rapidly in global clinical guidelines, how should we evaluate, select and apply it? These questions need to be answered using a systematic and scientific approach."
    },
    {
      "paragraph_id": "4",
      "paragraph": "本指南采用GRADE(the Grading of Recommendation Assessment，Development and Evaluation)证据质量评价与推荐强度系统。证据量评价：A表示高质量，B表示中等质量，C表示低质量，D表示极低质量；推荐强度：1表示强推荐，2表示弱推荐，0表示无明确推荐意见。(见表2、3)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "本指南采用GRADE(the Grading of Recommendation Assessment，Development and Evaluation)证据质量评价与推荐强度系统。",
          "start_idx": 0,
          "end_idx": 93,
          "entities": [],
          "relations": [],
          "sentence_en": "This guideline adopts the GRADE (Grading of Recommendation Assessment, Development and Evaluation) system for evaluating the quality of evidence and the strength of recommendations."
        },
        {
          "sentence_id": "1",
          "sentence": "证据量评价：A表示高质量，B表示中等质量，C表示低质量，D表示极低质量；推荐强度：1表示强推荐，2表示弱推荐，0表示无明确推荐意见。",
          "start_idx": 93,
          "end_idx": 159,
          "entities": [],
          "relations": [],
          "sentence_en": "Evaluation of the amount of evidence: A represents high quality, B represents moderate quality, C represents low quality, and D represents very low quality; Recommendation strength: 1 represents strong recommendation, 2 represents weak recommendation, and 0 represents no clear recommendation."
        },
        {
          "sentence_id": "2",
          "sentence": "(见表2、3)",
          "start_idx": 159,
          "end_idx": 166,
          "entities": [],
          "relations": [],
          "sentence_en": "(See Table 2, 3)"
        }
      ],
      "paragraph_en": "This guideline adopts the GRADE (Grading of Recommendation Assessment, Development and Evaluation) system for evidence quality evaluation and recommendation strength. Evidence quality evaluation: A represents high quality, B represents medium quality, C represents low quality, and D represents very low quality; recommendation strength: 1 represents strong recommendation, 2 represents weak recommendation, and 0 represents no clear recommendation. (See Tables 2 and 3)"
    },
    {
      "paragraph_id": "5",
      "paragraph": "临床问题1：DPP-4i是否可作为2型糖尿病患者的一线治疗选择之一?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题1：DPP-4i是否可作为2型糖尿病患者的一线治疗选择之一?",
          "start_idx": 0,
          "end_idx": 34,
          "entities": [
            {
              "entity_id": "T10",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T11",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 22,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T12",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R0",
              "head_entity_id": "T10",
              "tail_entity_id": "T11"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R1",
              "head_entity_id": "T12",
              "tail_entity_id": "T11"
            }
          ],
          "sentence_en": "Clinical question 1: Can DPP-4i be used as a first-line treatment option for patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical question 1: Can DPP-4i be used as a first-line treatment option for patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "6",
      "paragraph": "推荐意见 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "7",
      "paragraph": "推荐D PP-4i作为2型糖尿病患者的一线治疗选择之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐D PP-4i作为2型糖尿病患者的一线治疗选择之一。",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T13",
              "entity": "D PP-4i",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "D PP-4i"
            },
            {
              "entity_id": "T14",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T15",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R2",
              "head_entity_id": "T13",
              "tail_entity_id": "T14"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T15",
              "tail_entity_id": "T14"
            }
          ],
          "sentence_en": "DPP-4i is recommended as one of the first-line treatment options for patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "DPP-4i is recommended as one of the first-line treatment options for patients with type 2 diabetes."
    },
    {
      "paragraph_id": "8",
      "paragraph": "推荐说明",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "9",
      "paragraph": "二甲双胍被各国指南推荐作为2型糖尿病患者的一线治疗药物。在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4i可以作为一线的替代治疗药物。DPP-4i的推荐剂量为说明书中规定的常规使用剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍被各国指南推荐作为2型糖尿病患者的一线治疗药物。",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T16",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T17",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T18",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R4",
              "head_entity_id": "T16",
              "tail_entity_id": "T17"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R5",
              "head_entity_id": "T18",
              "tail_entity_id": "T17"
            }
          ],
          "sentence_en": "Metformin is recommended by national guidelines as the first-line treatment for patients with type 2 diabetes."
        },
        {
          "sentence_id": "1",
          "sentence": "在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4i可以作为一线的替代治疗药物。",
          "start_idx": 28,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T19",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T20",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 26,
              "entity_en": "DPP-4i"
            }
          ],
          "relations": [],
          "sentence_en": "In cases of metformin intolerance or contraindications, DPP-4i can be used as a first-line alternative treatment."
        },
        {
          "sentence_id": "2",
          "sentence": "DPP-4i的推荐剂量为说明书中规定的常规使用剂量。",
          "start_idx": 68,
          "end_idx": 94,
          "entities": [
            {
              "entity_id": "T21",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "DPP-4i"
            }
          ],
          "relations": [],
          "sentence_en": "The recommended dose of DPP-4i is the usual dose specified in the instructions."
        }
      ],
      "paragraph_en": "Metformin is recommended by national guidelines as a first-line treatment for patients with type 2 diabetes. In cases of metformin intolerance or contraindications, DPP-4i can be used as a first-line alternative treatment. The recommended dose of DPP-4i is the regular dose specified in the instructions."
    },
    {
      "paragraph_id": "10",
      "paragraph": "推荐等级：1 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：1 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 1"
        }
      ],
      "paragraph_en": "Recommended level: 1"
    },
    {
      "paragraph_id": "11",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "12",
      "paragraph": "临床问题2：在单药治疗血糖控制不佳情况下，DPP-4i是否可作为2型糖尿病患者的二线治疗选择之一? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题2：在单药治疗血糖控制不佳情况下，DPP-4i是否可作为2型糖尿病患者的二线治疗选择之一? ",
          "start_idx": 0,
          "end_idx": 50,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T23",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 27,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T24",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T25",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T26",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Poor control"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R6",
              "head_entity_id": "T22",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R7",
              "head_entity_id": "T23",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R8",
              "head_entity_id": "T25",
              "tail_entity_id": "T24"
            }
          ],
          "sentence_en": "Clinical question 2: When monotherapy fails to achieve adequate glycemic control, can DPP-4i be used as a second-line treatment option for patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical question 2: When monotherapy fails to achieve adequate glycemic control, can DPP-4i be used as a second-line treatment option for patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "13",
      "paragraph": "推荐意见 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "14",
      "paragraph": "推荐DPP-4i作为2型糖尿病患者的二线治疗之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐DPP-4i作为2型糖尿病患者的二线治疗之一。",
          "start_idx": 0,
          "end_idx": 25,
          "entities": [
            {
              "entity_id": "T27",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T28",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T29",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R9",
              "head_entity_id": "T27",
              "tail_entity_id": "T28"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R10",
              "head_entity_id": "T29",
              "tail_entity_id": "T28"
            }
          ],
          "sentence_en": "DPP-4i is recommended as one of the second-line treatments for patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "DPP-4i is recommended as one of the second-line treatments for patients with type 2 diabetes."
    },
    {
      "paragraph_id": "15",
      "paragraph": "推荐说明 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "16",
      "paragraph": "当二甲双胍或者其他降糖药物单药治疗后，糖化血红蛋白水平仍未达标，则需联合另外一种降糖药治疗。推荐等级：1 证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "当二甲双胍或者其他降糖药物单药治疗后，糖化血红蛋白水平仍未达标，则需联合另外一种降糖药治疗。",
          "start_idx": 0,
          "end_idx": 46,
          "entities": [
            {
              "entity_id": "T30",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T31",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 19,
              "end_idx": 25,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T32",
              "entity": "未达标",
              "entity_type": "Test_Value",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "Not up to standard"
            }
          ],
          "relations": [],
          "sentence_en": "When the glycated hemoglobin level still does not reach the target after monotherapy with metformin or other hypoglycemic drugs, another hypoglycemic drug should be used in combination."
        },
        {
          "sentence_id": "1",
          "sentence": "推荐等级：1 证据级别：B",
          "start_idx": 46,
          "end_idx": 59,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendation level: 1 Evidence level: B"
        }
      ],
      "paragraph_en": "When the glycated hemoglobin level is still not up to standard after monotherapy with metformin or other hypoglycemic drugs, another hypoglycemic drug should be used in combination. Recommendation level: 1 Evidence level: B"
    },
    {
      "paragraph_id": "17",
      "paragraph": "临床问题3：在二线治疗控制不佳情况下，DPP-4i是否可作为2型糖尿病患者的三线治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题3：在二线治疗控制不佳情况下，DPP-4i是否可作为2型糖尿病患者的三线治疗",
          "start_idx": 0,
          "end_idx": 42,
          "entities": [
            {
              "entity_id": "T33",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 25,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T34",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T35",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R11",
              "head_entity_id": "T33",
              "tail_entity_id": "T34"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R12",
              "head_entity_id": "T35",
              "tail_entity_id": "T34"
            }
          ],
          "sentence_en": "Clinical question 3: Can DPP-4i be used as a third-line treatment for patients with type 2 diabetes when second-line treatment is inadequately controlled?"
        }
      ],
      "paragraph_en": "Clinical question 3: Can DPP-4i be used as a third-line treatment for patients with type 2 diabetes when second-line treatment is inadequately controlled?"
    },
    {
      "paragraph_id": "18",
      "paragraph": "选择之一?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "选择之一?",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Choose one?"
        }
      ],
      "paragraph_en": "Choose one?"
    },
    {
      "paragraph_id": "19",
      "paragraph": "推荐意见推荐DPP-4i作为2型糖尿病患者的三线治疗选择之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见推荐DPP-4i作为2型糖尿病患者的三线治疗选择之一。",
          "start_idx": 0,
          "end_idx": 31,
          "entities": [
            {
              "entity_id": "T36",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T37",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T38",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R13",
              "head_entity_id": "T36",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R14",
              "head_entity_id": "T38",
              "tail_entity_id": "T37"
            }
          ],
          "sentence_en": "Recommendations: DPP-4i is recommended as one of the third-line treatment options for patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Recommendations: DPP-4i is recommended as one of the third-line treatment options for patients with type 2 diabetes."
    },
    {
      "paragraph_id": "20",
      "paragraph": "推荐说明 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "21",
      "paragraph": "由于DPP-4i具有较好的有效性和安全性，在二线治疗时仍未使用DPP-4i治疗的患者，推荐DPP-4i作为2型糖尿病患者的三线治疗选择之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于DPP-4i具有较好的有效性和安全性，在二线治疗时仍未使用DPP-4i治疗的患者，推荐DPP-4i作为2型糖尿病患者的三线治疗选择之一。",
          "start_idx": 0,
          "end_idx": 70,
          "entities": [
            {
              "entity_id": "T39",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T40",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 37,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T41",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 51,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T42",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 58,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T43",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 53,
              "end_idx": 55,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R15",
              "head_entity_id": "T41",
              "tail_entity_id": "T42"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R16",
              "head_entity_id": "T43",
              "tail_entity_id": "T42"
            }
          ],
          "sentence_en": "Because DPP-4i has good efficacy and safety, it is recommended as one of the third-line treatment options for patients with type 2 diabetes who have not yet received DPP-4i treatment as a second-line treatment."
        }
      ],
      "paragraph_en": "Because DPP-4i has good efficacy and safety, it is recommended as one of the third-line treatment options for patients with type 2 diabetes who have not yet received DPP-4i treatment as a second-line treatment."
    },
    {
      "paragraph_id": "22",
      "paragraph": "推荐等级：1 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：1 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 1"
        }
      ],
      "paragraph_en": "Recommended level: 1"
    },
    {
      "paragraph_id": "23",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "24",
      "paragraph": "临床问题4：DPP-4i联合基础胰岛素是否可用于2型糖尿病患者的降糖治疗?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题4：DPP-4i联合基础胰岛素是否可用于2型糖尿病患者的降糖治疗?",
          "start_idx": 0,
          "end_idx": 37,
          "entities": [
            {
              "entity_id": "T44",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T45",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T46",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T47",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R17",
              "head_entity_id": "T44",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R18",
              "head_entity_id": "T45",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R19",
              "head_entity_id": "T47",
              "tail_entity_id": "T46"
            }
          ],
          "sentence_en": "Clinical question 4: Can DPP-4i combined with basal insulin be used for glucose-lowering treatment in patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical question 4: Can DPP-4i combined with basal insulin be used for glucose-lowering treatment in patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "25",
      "paragraph": "推荐意见 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "26",
      "paragraph": "推荐DPP-4i联合基础胰岛素用于2型糖尿病的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐DPP-4i联合基础胰岛素用于2型糖尿病的降糖治疗。",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T48",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T49",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T50",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 22,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T51",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R20",
              "head_entity_id": "T48",
              "tail_entity_id": "T50"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R21",
              "head_entity_id": "T49",
              "tail_entity_id": "T50"
            }
          ],
          "sentence_en": "DPP-4i combined with basal insulin is recommended for glucose-lowering treatment of type 2 diabetes."
        }
      ],
      "paragraph_en": "DPP-4i combined with basal insulin is recommended for glucose-lowering treatment of type 2 diabetes."
    },
    {
      "paragraph_id": "27",
      "paragraph": "推荐说明 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "28",
      "paragraph": "当使用基础胰岛素进行治疗，糖化血红蛋白控制不佳时，可添加DPP-4i进行联合治疗，并根据糖化血红蛋白水平，调整胰岛素的剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "当使用基础胰岛素进行治疗，糖化血红蛋白控制不佳时，可添加DPP-4i进行联合治疗，并根据糖化血红蛋白水平，调整胰岛素的剂量。",
          "start_idx": 0,
          "end_idx": 62,
          "entities": [
            {
              "entity_id": "T52",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T53",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 13,
              "end_idx": 19,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T54",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 19,
              "end_idx": 23,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T55",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 34,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T56",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 44,
              "end_idx": 50,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T57",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 58,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "When basal insulin is used for treatment and glycated hemoglobin is not well controlled, DPP-4i can be added for combination therapy, and the insulin dose can be adjusted according to the glycated hemoglobin level."
        }
      ],
      "paragraph_en": "When basal insulin is used for treatment and glycated hemoglobin is not well controlled, DPP-4i can be added for combination therapy, and the insulin dose can be adjusted according to the glycated hemoglobin level."
    },
    {
      "paragraph_id": "29",
      "paragraph": "推荐等级：1 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：1 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 1"
        }
      ],
      "paragraph_en": "Recommended level: 1"
    },
    {
      "paragraph_id": "30",
      "paragraph": " 证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": " 证据级别：B",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "31",
      "paragraph": "临床问题5：DPP-4i是否可用于65岁以上的2型糖尿病患者的降糖治疗? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题5：DPP-4i是否可用于65岁以上的2型糖尿病患者的降糖治疗? ",
          "start_idx": 0,
          "end_idx": 37,
          "entities": [
            {
              "entity_id": "T58",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T59",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T60",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R22",
              "head_entity_id": "T58",
              "tail_entity_id": "T59"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R23",
              "head_entity_id": "T60",
              "tail_entity_id": "T59"
            }
          ],
          "sentence_en": "Clinical Question 5: Can DPP-4i be used for glucose-lowering treatment in patients with type 2 diabetes over 65 years old?"
        }
      ],
      "paragraph_en": "Clinical Question 5: Can DPP-4i be used for glucose-lowering treatment in patients with type 2 diabetes over 65 years old?"
    },
    {
      "paragraph_id": "32",
      "paragraph": "推荐意见",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "33",
      "paragraph": "推荐DPP-4i用于65岁以上的2型糖尿病患者糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐DPP-4i用于65岁以上的2型糖尿病患者糖治疗。",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T61",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T62",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 21,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T63",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R24",
              "head_entity_id": "T61",
              "tail_entity_id": "T62"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R25",
              "head_entity_id": "T63",
              "tail_entity_id": "T62"
            }
          ],
          "sentence_en": "DPP-4i is recommended for the treatment of type 2 diabetes in patients over 65 years of age."
        }
      ],
      "paragraph_en": "DPP-4i is recommended for the treatment of type 2 diabetes in patients over 65 years of age."
    },
    {
      "paragraph_id": "34",
      "paragraph": "推荐说明",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "35",
      "paragraph": "由于老年患者常常合并多种并发疾病，DPP-4i具有良好的血糖控制效果和安全性，推荐DPP-4i用于老年2型糖尿病患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于老年患者常常合并多种并发疾病，DPP-4i具有良好的血糖控制效果和安全性，推荐DPP-4i用于老年2型糖尿病患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T64",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 23,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T65",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T66",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 47,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T67",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 51,
              "end_idx": 56,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T68",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 51,
              "end_idx": 53,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R26",
              "head_entity_id": "T65",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R27",
              "head_entity_id": "T66",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R28",
              "head_entity_id": "T68",
              "tail_entity_id": "T67"
            }
          ],
          "sentence_en": "Since elderly patients often have multiple concurrent diseases, DPP-4i has good blood sugar control effect and safety. DPP-4i is recommended for hypoglycemic treatment of elderly patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Since elderly patients often have multiple concurrent diseases, DPP-4i has good blood sugar control effect and safety. DPP-4i is recommended for hypoglycemic treatment of elderly patients with type 2 diabetes."
    },
    {
      "paragraph_id": "36",
      "paragraph": "推荐使用常规剂量进行治疗，除非伴有肝或肾功能不全，需根据说明书进行剂量调整。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐使用常规剂量进行治疗，除非伴有肝或肾功能不全，需根据说明书进行剂量调整。",
          "start_idx": 0,
          "end_idx": 38,
          "entities": [
            {
              "entity_id": "T69",
              "entity": "肝或肾功能不全",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 24,
              "entity_en": "Hepatic or renal impairment"
            },
            {
              "entity_id": "T70",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 18,
              "entity_en": "liver"
            },
            {
              "entity_id": "T71",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 19,
              "end_idx": 20,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R29",
              "head_entity_id": "T70",
              "tail_entity_id": "T69"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R30",
              "head_entity_id": "T71",
              "tail_entity_id": "T69"
            }
          ],
          "sentence_en": "Conventional doses are recommended for treatment unless there is liver or renal insufficiency, in which case the dose should be adjusted according to the instructions."
        }
      ],
      "paragraph_en": "Conventional doses are recommended for treatment unless there is liver or renal insufficiency, in which case the dose should be adjusted according to the instructions."
    },
    {
      "paragraph_id": "37",
      "paragraph": "推荐等级：1 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：1 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 1"
        }
      ],
      "paragraph_en": "Recommended level: 1"
    },
    {
      "paragraph_id": "38",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "39",
      "paragraph": "临床问题6：DPP-4i是否可用于超重/肥胖2型糖尿病患者的降糖治疗? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题6：DPP-4i是否可用于超重/肥胖2型糖尿病患者的降糖治疗? ",
          "start_idx": 0,
          "end_idx": 36,
          "entities": [
            {
              "entity_id": "T72",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T73",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T74",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T75",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T76",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R31",
              "head_entity_id": "T72",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R32",
              "head_entity_id": "T76",
              "tail_entity_id": "T75"
            }
          ],
          "sentence_en": "Clinical Question 6: Can DPP-4i be used for glucose-lowering treatment in overweight/obese patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical Question 6: Can DPP-4i be used for glucose-lowering treatment in overweight/obese patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "40",
      "paragraph": "推荐意见DPP-4i可用于超重/肥胖2型糖尿病患者的降疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见DPP-4i可用于超重/肥胖2型糖尿病患者的降疗。",
          "start_idx": 0,
          "end_idx": 29,
          "entities": [
            {
              "entity_id": "T77",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 10,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T78",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T79",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T80",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T81",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R33",
              "head_entity_id": "T77",
              "tail_entity_id": "T80"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R34",
              "head_entity_id": "T81",
              "tail_entity_id": "T80"
            }
          ],
          "sentence_en": "Recommendation: DPP-4i can be used to reduce the incidence of type 2 diabetes in overweight/obese patients."
        }
      ],
      "paragraph_en": "Recommendation: DPP-4i can be used to reduce the incidence of type 2 diabetes in overweight/obese patients."
    },
    {
      "paragraph_id": "41",
      "paragraph": "推荐说明",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "42",
      "paragraph": "由于DPP-4i不影响患者的体重，故建议DPP-4i用于超重/肥胖2型糖尿病患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于DPP-4i不影响患者的体重，故建议DPP-4i用于超重/肥胖2型糖尿病患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 46,
          "entities": [
            {
              "entity_id": "T82",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 8,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T83",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 26,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T84",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T85",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 33,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T86",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T87",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R35",
              "head_entity_id": "T83",
              "tail_entity_id": "T86"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R36",
              "head_entity_id": "T87",
              "tail_entity_id": "T86"
            }
          ],
          "sentence_en": "Since DPP-4i does not affect the patient's weight, it is recommended that DPP-4i be used for glucose-lowering treatment in overweight/obese patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Since DPP-4i does not affect the patient's weight, it is recommended that DPP-4i be used for glucose-lowering treatment in overweight/obese patients with type 2 diabetes."
    },
    {
      "paragraph_id": "43",
      "paragraph": "推荐等级：2 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：2 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 2"
        }
      ],
      "paragraph_en": "Recommended level: 2"
    },
    {
      "paragraph_id": "44",
      "paragraph": "证据级别：C",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：C",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Evidence Level: C"
        }
      ],
      "paragraph_en": "Evidence Level: C"
    },
    {
      "paragraph_id": "45",
      "paragraph": "临床问题7：DPP-4i是否可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗? 推荐意见",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题7：DPP-4i是否可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗? 推荐意见",
          "start_idx": 0,
          "end_idx": 51,
          "entities": [
            {
              "entity_id": "T88",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 12,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T89",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T90",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T91",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T92",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 30,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T93",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T94",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R37",
              "head_entity_id": "T88",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R38",
              "head_entity_id": "T90",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R39",
              "head_entity_id": "T93",
              "tail_entity_id": "T91"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R40",
              "head_entity_id": "T94",
              "tail_entity_id": "T92"
            }
          ],
          "sentence_en": "Clinical Question 7: Can DPP-4i be used for glucose-lowering treatment in patients with type 2 diabetes who are at risk of cardiovascular disease or cardiovascular events? Recommendation"
        }
      ],
      "paragraph_en": "Clinical Question 7: Can DPP-4i be used for glucose-lowering treatment in patients with type 2 diabetes who are at risk of cardiovascular disease or cardiovascular events? Recommendation"
    },
    {
      "paragraph_id": "46",
      "paragraph": "DPP-4i可用于伴有心血管疾病或心血管事件的2型糖尿病患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "DPP-4i可用于伴有心血管疾病或心血管事件的2型糖尿病患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 36,
          "entities": [
            {
              "entity_id": "T95",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T96",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T97",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T98",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T99",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T100",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 22,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T101",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R41",
              "head_entity_id": "T95",
              "tail_entity_id": "T96"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R42",
              "head_entity_id": "T97",
              "tail_entity_id": "T96"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R43",
              "head_entity_id": "T99",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R44",
              "head_entity_id": "T101",
              "tail_entity_id": "T100"
            }
          ],
          "sentence_en": "DPP-4i can be used for glucose-lowering treatment in patients with type 2 diabetes mellitus who have cardiovascular disease or cardiovascular events."
        }
      ],
      "paragraph_en": "DPP-4i can be used for glucose-lowering treatment in patients with type 2 diabetes mellitus who have cardiovascular disease or cardiovascular events."
    },
    {
      "paragraph_id": "47",
      "paragraph": "推荐说明 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "48",
      "paragraph": "基于证据总结和专家意见，DPP-4i可用于血管疾病或心血管事件风险的2型糖尿病患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "基于证据总结和专家意见，DPP-4i可用于血管疾病或心血管事件风险的2型糖尿病患者。",
          "start_idx": 0,
          "end_idx": 42,
          "entities": [
            {
              "entity_id": "T102",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 18,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T103",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 39,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T104",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T105",
              "entity": "血管疾病",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Vascular disease"
            },
            {
              "entity_id": "T106",
              "entity": "血管",
              "entity_type": "Anatomy",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "Blood vessel"
            },
            {
              "entity_id": "T107",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 31,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T108",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 26,
              "end_idx": 29,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R45",
              "head_entity_id": "T102",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R46",
              "head_entity_id": "T104",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R47",
              "head_entity_id": "T106",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R48",
              "head_entity_id": "T108",
              "tail_entity_id": "T107"
            }
          ],
          "sentence_en": "Based on the evidence summary and expert opinion, DPP-4i can be used in patients with type 2 diabetes who have vascular disease or are at risk for cardiovascular events."
        }
      ],
      "paragraph_en": "Based on the evidence summary and expert opinion, DPP-4i can be used in patients with type 2 diabetes who have vascular disease or are at risk for cardiovascular events."
    },
    {
      "paragraph_id": "49",
      "paragraph": "推荐等级：2 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：2 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 2"
        }
      ],
      "paragraph_en": "Recommended level: 2"
    },
    {
      "paragraph_id": "50",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "51",
      "paragraph": "临床问题8：复方制剂(DPP-4i和二甲双胍)是否可用于2型糖尿病患者的起始降糖治疗? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题8：复方制剂(DPP-4i和二甲双胍)是否可用于2型糖尿病患者的起始降糖治疗? ",
          "start_idx": 0,
          "end_idx": 44,
          "entities": [
            {
              "entity_id": "T109",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 17,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T110",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T111",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 33,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T112",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R49",
              "head_entity_id": "T109",
              "tail_entity_id": "T111"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R50",
              "head_entity_id": "T110",
              "tail_entity_id": "T111"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R51",
              "head_entity_id": "T112",
              "tail_entity_id": "T111"
            }
          ],
          "sentence_en": "Clinical Question 8: Can combination preparations (DPP-4i and metformin) be used for the initial glucose-lowering treatment of patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical Question 8: Can combination preparations (DPP-4i and metformin) be used for the initial glucose-lowering treatment of patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "52",
      "paragraph": "推荐意见",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "53",
      "paragraph": "推荐复方制剂(DPP-4i和二甲双胍)用于2型糖病患者的起始降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐复方制剂(DPP-4i和二甲双胍)用于2型糖病患者的起始降糖治疗。",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [
            {
              "entity_id": "T113",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 13,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T114",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T115",
              "entity": "2型糖病",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T116",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R52",
              "head_entity_id": "T113",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T114",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R54",
              "head_entity_id": "T116",
              "tail_entity_id": "T115"
            }
          ],
          "sentence_en": "Combination preparations (DPP-4i and metformin) are recommended for the initial glucose-lowering treatment of patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Combination preparations (DPP-4i and metformin) are recommended for the initial glucose-lowering treatment of patients with type 2 diabetes."
    },
    {
      "paragraph_id": "54",
      "paragraph": "推荐说明",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "55",
      "paragraph": "对于HbA1c>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4i和二甲双胍)进行起始治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于HbA1c>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4i和二甲双胍)进行起始治疗。",
          "start_idx": 0,
          "end_idx": 48,
          "entities": [
            {
              "entity_id": "T117",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T118",
              "entity": ">7.5%",
              "entity_type": "Test_Value",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": ">7.5%"
            },
            {
              "entity_id": "T119",
              "entity": "DPP-4i",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 35,
              "entity_en": "DPP-4i"
            },
            {
              "entity_id": "T120",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 40,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "For patients with HbA1c>7.5% undergoing treatment for the first time, a combination preparation (DPP-4i and metformin) is recommended for initial treatment."
        }
      ],
      "paragraph_en": "For patients with HbA1c>7.5% undergoing treatment for the first time, a combination preparation (DPP-4i and metformin) is recommended for initial treatment."
    },
    {
      "paragraph_id": "56",
      "paragraph": "推荐等级：1 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：1 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 1"
        }
      ],
      "paragraph_en": "Recommended level: 1"
    },
    {
      "paragraph_id": "57",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "58",
      "paragraph": "临床问题9：在单药治疗血糖控制不佳情况下，GLP-1RA是否可作为2型糖尿病患者的二线治疗选择之一? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题9：在单药治疗血糖控制不佳情况下，GLP-1RA是否可作为2型糖尿病患者的二线治疗选择之一? ",
          "start_idx": 0,
          "end_idx": 51,
          "entities": [
            {
              "entity_id": "T121",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T122",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T123",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 28,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T124",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T125",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R55",
              "head_entity_id": "T121",
              "tail_entity_id": "T124"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R56",
              "head_entity_id": "T123",
              "tail_entity_id": "T124"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R57",
              "head_entity_id": "T125",
              "tail_entity_id": "T124"
            }
          ],
          "sentence_en": "Clinical Question 9: When monotherapy fails to achieve adequate glycemic control, can GLP-1RA be used as a second-line treatment option for patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical Question 9: When monotherapy fails to achieve adequate glycemic control, can GLP-1RA be used as a second-line treatment option for patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "59",
      "paragraph": "推荐意见 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "60",
      "paragraph": "推荐GLP—1RA作为2型糖尿病患者的二线治疗择之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐GLP—1RA作为2型糖尿病患者的二线治疗择之一。",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T126",
              "entity": "GLP—1RA",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T127",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T128",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T126",
              "tail_entity_id": "T127"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R59",
              "head_entity_id": "T128",
              "tail_entity_id": "T127"
            }
          ],
          "sentence_en": "GLP-1RA is recommended as one of the second-line treatment options for patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "GLP-1RA is recommended as one of the second-line treatment options for patients with type 2 diabetes."
    },
    {
      "paragraph_id": "61",
      "paragraph": "推荐说明 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "62",
      "paragraph": "由于GLP一1RA具有较好控制血糖和降低体重的作用，在单药治疗血糖控制不佳的情况，推荐GLP—1RA作为2型糖尿病患者的治疗选择。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于GLP一1RA具有较好控制血糖和降低体重的作用，在单药治疗血糖控制不佳的情况，推荐GLP—1RA作为2型糖尿病患者的治疗选择。",
          "start_idx": 0,
          "end_idx": 65,
          "entities": [
            {
              "entity_id": "T129",
              "entity": "GLP一1RA",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T130",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T131",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 31,
              "end_idx": 33,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T132",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 33,
              "end_idx": 37,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T133",
              "entity": "GLP—1RA",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 50,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T134",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 57,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T135",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 52,
              "end_idx": 54,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R60",
              "head_entity_id": "T131",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R61",
              "head_entity_id": "T133",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R62",
              "head_entity_id": "T135",
              "tail_entity_id": "T134"
            }
          ],
          "sentence_en": "Because GLP-1RA has a good effect on controlling blood sugar and reducing weight, when blood sugar control is poor with monotherapy, GLP-1RA is recommended as a treatment option for patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Because GLP-1RA has a good effect on controlling blood sugar and reducing weight, when blood sugar control is poor with monotherapy, GLP-1RA is recommended as a treatment option for patients with type 2 diabetes."
    },
    {
      "paragraph_id": "63",
      "paragraph": "推荐等级：1 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：1 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 1"
        }
      ],
      "paragraph_en": "Recommended level: 1"
    },
    {
      "paragraph_id": "64",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "65",
      "paragraph": "临床问题10：在二线治疗控制不佳情况下，GLP-1RA是否可作为2型糖尿病患者的三线治疗选择之一?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题10：在二线治疗控制不佳情况下，GLP-1RA是否可作为2型糖尿病患者的三线治疗选择之一?",
          "start_idx": 0,
          "end_idx": 49,
          "entities": [
            {
              "entity_id": "T136",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 27,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T137",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T138",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R63",
              "head_entity_id": "T136",
              "tail_entity_id": "T137"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R64",
              "head_entity_id": "T138",
              "tail_entity_id": "T137"
            }
          ],
          "sentence_en": "Clinical Question 10: If the second-line treatment is not adequately controlled, can GLP-1RA be used as a third-line treatment option for patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical Question 10: If the second-line treatment is not adequately controlled, can GLP-1RA be used as a third-line treatment option for patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "66",
      "paragraph": "推荐意见",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "67",
      "paragraph": "推荐GLP一1RA作为2型糖尿病患者的三线治疗选择之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐GLP一1RA作为2型糖尿病患者的三线治疗选择之一。",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T139",
              "entity": "GLP一1RA",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T140",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T141",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R65",
              "head_entity_id": "T139",
              "tail_entity_id": "T140"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R66",
              "head_entity_id": "T141",
              "tail_entity_id": "T140"
            }
          ],
          "sentence_en": "GLP-1RA is recommended as one of the third-line treatment options for patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "GLP-1RA is recommended as one of the third-line treatment options for patients with type 2 diabetes."
    },
    {
      "paragraph_id": "68",
      "paragraph": "推荐说明",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "69",
      "paragraph": "由于GLP—1RA具有较好的血糖控制效果，在二线治疗时血糖仍控制不佳的患者，推荐GLP-1RA作为2型糖尿病患者的三线治疗选择之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于GLP—1RA具有较好的血糖控制效果，在二线治疗时血糖仍控制不佳的患者，推荐GLP-1RA作为2型糖尿病患者的三线治疗选择之一。",
          "start_idx": 0,
          "end_idx": 66,
          "entities": [
            {
              "entity_id": "T142",
              "entity": "GLP—1RA",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T143",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T144",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T145",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 30,
              "end_idx": 34,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T146",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 47,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T147",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 54,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T148",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R67",
              "head_entity_id": "T144",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R68",
              "head_entity_id": "T146",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R69",
              "head_entity_id": "T148",
              "tail_entity_id": "T147"
            }
          ],
          "sentence_en": "Because GLP-1RA has a good blood sugar control effect, for patients whose blood sugar is still poorly controlled during second-line treatment, GLP-1RA is recommended as one of the third-line treatment options for patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Because GLP-1RA has a good blood sugar control effect, for patients whose blood sugar is still poorly controlled during second-line treatment, GLP-1RA is recommended as one of the third-line treatment options for patients with type 2 diabetes."
    },
    {
      "paragraph_id": "70",
      "paragraph": "推荐等级：1 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：1 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 1"
        }
      ],
      "paragraph_en": "Recommended level: 1"
    },
    {
      "paragraph_id": "71",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "72",
      "paragraph": "临床问题11：GLP-1RA联合基础胰岛素是否可用于2型糖尿病患者的降糖治疗?",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题11：GLP-1RA联合基础胰岛素是否可用于2型糖尿病患者的降糖治疗?",
          "start_idx": 0,
          "end_idx": 39,
          "entities": [
            {
              "entity_id": "T149",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 14,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T150",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T151",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 31,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T152",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R70",
              "head_entity_id": "T149",
              "tail_entity_id": "T151"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R71",
              "head_entity_id": "T150",
              "tail_entity_id": "T151"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R72",
              "head_entity_id": "T152",
              "tail_entity_id": "T151"
            }
          ],
          "sentence_en": "Clinical Question 11: Can GLP-1RA combined with basal insulin be used for glucose-lowering treatment in patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical Question 11: Can GLP-1RA combined with basal insulin be used for glucose-lowering treatment in patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "73",
      "paragraph": "推荐意见推荐GLP一1RA联合基础胰岛素用于2型糖尿病患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见推荐GLP一1RA联合基础胰岛素用于2型糖尿病患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [
            {
              "entity_id": "T153",
              "entity": "GLP一1RA",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 13,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T154",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T155",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T156",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R73",
              "head_entity_id": "T153",
              "tail_entity_id": "T155"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R74",
              "head_entity_id": "T154",
              "tail_entity_id": "T155"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R75",
              "head_entity_id": "T156",
              "tail_entity_id": "T155"
            }
          ],
          "sentence_en": "Recommendations: GLP-1RA combined with basal insulin is recommended for glucose-lowering treatment in patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Recommendations: GLP-1RA combined with basal insulin is recommended for glucose-lowering treatment in patients with type 2 diabetes."
    },
    {
      "paragraph_id": "74",
      "paragraph": "推荐说明",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "75",
      "paragraph": "当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，可添GLP-1RA进行联合治疗并根据糖化血红蛋白水平，调整胰岛素的剂量。推荐等级：1",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，可添GLP-1RA进行联合治疗并根据糖化血红蛋白水平，调整胰岛素的剂量。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T157",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T158",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 13,
              "end_idx": 19,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T159",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T160",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 37,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T161",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 52,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T162",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "When basal insulin is used for treatment and the glycated hemoglobin level is still poorly controlled, GLP-1RA can be added for combined treatment and the insulin dose can be adjusted according to the glycated hemoglobin level."
        },
        {
          "sentence_id": "1",
          "sentence": "推荐等级：1",
          "start_idx": 64,
          "end_idx": 70,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 1"
        }
      ],
      "paragraph_en": "When basal insulin is used for treatment and the glycated hemoglobin level is still poorly controlled, GLP-1RA can be added for combined treatment and the insulin dose can be adjusted according to the glycated hemoglobin level. Recommendation level: 1"
    },
    {
      "paragraph_id": "76",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "77",
      "paragraph": "临床问题12：GLP-1RA是否可用于超重/肥胖2型糖尿病患者的降糖治疗? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题12：GLP-1RA是否可用于超重/肥胖2型糖尿病患者的降糖治疗? ",
          "start_idx": 0,
          "end_idx": 38,
          "entities": [
            {
              "entity_id": "T163",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 14,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T164",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T165",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T166",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T167",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R76",
              "head_entity_id": "T163",
              "tail_entity_id": "T166"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R77",
              "head_entity_id": "T167",
              "tail_entity_id": "T166"
            }
          ],
          "sentence_en": "Clinical Question 12: Can GLP-1RA be used for glucose-lowering treatment in overweight/obese patients with type 2 diabetes?"
        }
      ],
      "paragraph_en": "Clinical Question 12: Can GLP-1RA be used for glucose-lowering treatment in overweight/obese patients with type 2 diabetes?"
    },
    {
      "paragraph_id": "78",
      "paragraph": "推荐意见 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "79",
      "paragraph": "建议GLP-1RA用于超重/fie胖2型糖尿病患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "建议GLP-1RA用于超重/fie胖2型糖尿病患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 31,
          "entities": [
            {
              "entity_id": "T168",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T169",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T170",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T171",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R78",
              "head_entity_id": "T168",
              "tail_entity_id": "T170"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R79",
              "head_entity_id": "T171",
              "tail_entity_id": "T170"
            }
          ],
          "sentence_en": "GLP-1RA is recommended for glucose-lowering treatment in overweight/obese patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "GLP-1RA is recommended for glucose-lowering treatment in overweight/obese patients with type 2 diabetes."
    },
    {
      "paragraph_id": "80",
      "paragraph": "推荐说明 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "81",
      "paragraph": "由于GLP-1RA可显著降低患者体重，对于超重/肥胖的2型糖尿病患者，建议GLP-1RA用于超重/肥胖患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于GLP-1RA可显著降低患者体重，对于超重/肥胖的2型糖尿病患者，建议GLP-1RA用于超重/肥胖患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 59,
          "entities": [
            {
              "entity_id": "T172",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T173",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T174",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T175",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T176",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T177",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 44,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T178",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 48,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T179",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "obesity"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R80",
              "head_entity_id": "T172",
              "tail_entity_id": "T175"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T176",
              "tail_entity_id": "T175"
            }
          ],
          "sentence_en": "Since GLP-1RA can significantly reduce the patient's weight, it is recommended that GLP-1RA be used for hypoglycemic treatment in overweight/obese patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Since GLP-1RA can significantly reduce the patient's weight, it is recommended that GLP-1RA be used for hypoglycemic treatment in overweight/obese patients with type 2 diabetes."
    },
    {
      "paragraph_id": "82",
      "paragraph": "推荐等级：2 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：2 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 2"
        }
      ],
      "paragraph_en": "Recommended level: 2"
    },
    {
      "paragraph_id": "83",
      "paragraph": "证据级别：B",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：B",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Level of evidence: B"
        }
      ],
      "paragraph_en": "Level of evidence: B"
    },
    {
      "paragraph_id": "84",
      "paragraph": "临床问题13：GLP-1RA是否可用于伴有非酒精性脂肪肝的2型糖尿病患者的降糖治疗? ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床问题13：GLP-1RA是否可用于伴有非酒精性脂肪肝的2型糖尿病患者的降糖治疗? ",
          "start_idx": 0,
          "end_idx": 43,
          "entities": [
            {
              "entity_id": "T180",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 14,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T181",
              "entity": "非酒精性脂肪肝",
              "entity_type": "Disease",
              "start_idx": 21,
              "end_idx": 28,
              "entity_en": "Nonalcoholic fatty liver disease"
            },
            {
              "entity_id": "T182",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 27,
              "end_idx": 28,
              "entity_en": "liver"
            },
            {
              "entity_id": "T183",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T184",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 29,
              "end_idx": 31,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R82",
              "head_entity_id": "T180",
              "tail_entity_id": "T183"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R83",
              "head_entity_id": "T182",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R84",
              "head_entity_id": "T184",
              "tail_entity_id": "T183"
            }
          ],
          "sentence_en": "Clinical Question 13: Can GLP-1RA be used for glucose-lowering treatment in patients with type 2 diabetes and non-alcoholic fatty liver disease?"
        }
      ],
      "paragraph_en": "Clinical Question 13: Can GLP-1RA be used for glucose-lowering treatment in patients with type 2 diabetes and non-alcoholic fatty liver disease?"
    },
    {
      "paragraph_id": "85",
      "paragraph": "推荐意见 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐意见 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommendations"
        }
      ],
      "paragraph_en": "Recommendations"
    },
    {
      "paragraph_id": "86",
      "paragraph": "建议GLP-1RA用于伴有非酒精性脂肪肝2型糖尿病患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "建议GLP-1RA用于伴有非酒精性脂肪肝2型糖尿病患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 33,
          "entities": [
            {
              "entity_id": "T185",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T186",
              "entity": "非酒精性脂肪肝",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 20,
              "entity_en": "Nonalcoholic fatty liver disease"
            },
            {
              "entity_id": "T187",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 19,
              "end_idx": 20,
              "entity_en": "liver"
            },
            {
              "entity_id": "T188",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T189",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R85",
              "head_entity_id": "T185",
              "tail_entity_id": "T188"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R86",
              "head_entity_id": "T187",
              "tail_entity_id": "T186"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R87",
              "head_entity_id": "T189",
              "tail_entity_id": "T188"
            }
          ],
          "sentence_en": "GLP-1RA is recommended for glucose-lowering treatment in patients with type 2 diabetes and non-alcoholic fatty liver disease."
        }
      ],
      "paragraph_en": "GLP-1RA is recommended for glucose-lowering treatment in patients with type 2 diabetes and non-alcoholic fatty liver disease."
    },
    {
      "paragraph_id": "87",
      "paragraph": "推荐说明 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐说明 ",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended instructions"
        }
      ],
      "paragraph_en": "Recommended instructions"
    },
    {
      "paragraph_id": "88",
      "paragraph": "对于伴有非酒精性脂肪肝的2型糖尿病患者GLP-1RA可降低BMI和ALT水平，建议使用GLP-1RA进行治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于伴有非酒精性脂肪肝的2型糖尿病患者GLP-1RA可降低BMI和ALT水平，建议使用GLP-1RA进行治疗。",
          "start_idx": 0,
          "end_idx": 55,
          "entities": [
            {
              "entity_id": "T190",
              "entity": "非酒精性脂肪肝",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 11,
              "entity_en": "Nonalcoholic fatty liver disease"
            },
            {
              "entity_id": "T191",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 10,
              "end_idx": 11,
              "entity_en": "liver"
            },
            {
              "entity_id": "T192",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T193",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T194",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 26,
              "entity_en": "GLP-1RA"
            },
            {
              "entity_id": "T195",
              "entity": "ALT",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "ALT"
            },
            {
              "entity_id": "T196",
              "entity": "GLP-1RA",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 50,
              "entity_en": "GLP-1RA"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R88",
              "head_entity_id": "T191",
              "tail_entity_id": "T190"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R89",
              "head_entity_id": "T193",
              "tail_entity_id": "T192"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R90",
              "head_entity_id": "T194",
              "tail_entity_id": "T192"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R91",
              "head_entity_id": "T195",
              "tail_entity_id": "T192"
            }
          ],
          "sentence_en": "For patients with type 2 diabetes and non-alcoholic fatty liver disease, GLP-1RA can reduce BMI and ALT levels, and GLP-1RA is recommended for treatment."
        }
      ],
      "paragraph_en": "For patients with type 2 diabetes and non-alcoholic fatty liver disease, GLP-1RA can reduce BMI and ALT levels, and GLP-1RA is recommended for treatment."
    },
    {
      "paragraph_id": "89",
      "paragraph": "推荐等级：2 ",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "推荐等级：2 ",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Recommended level: 2"
        }
      ],
      "paragraph_en": "Recommended level: 2"
    },
    {
      "paragraph_id": "90",
      "paragraph": "证据级别：C",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据级别：C",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "Evidence Level: C"
        }
      ],
      "paragraph_en": "Evidence Level: C"
    }
  ]
}